Suicide/suicidal thoughts or clinical worsening
Depression is associated with an increased risk of suicidal thoughts, self harm and suicide (suicide related events). This risk persists until significant remission occurs. As improvement many not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.
Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared with placebo in patients less than 25 years old.
Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.
The once-a-day dosage regimen of Doxepin 50 mg Capsules in patients with intercurrent illness or patients taking other medications should be carefully adjusted. This is especially important in patients receiving other medications with anti-cholinergic effects.
The use of Doxepin 50 mg Capsules on a once-a-day dosage regimen in geriatric patients should be adjusted carefully on the basis of the patient's condition. The elderly are particularly liable to experience toxic effects, especially agitation, confusion and postural hypotension. The initial dose should be increased with caution under close supervision. Half the normal maintenance dose may be sufficient to produce a satisfactory clinical response.
Patients should be warned that drowsiness may occur with the use of Doxepin 50 mg Capsules. Patients should also be cautioned that their response to alcohol may be potentiated.
Although Doxepin 50 mg Capsules carry less risk than other tricyclic anti-depressants, caution should be observed in the treatment of patients with severe cardiovascular disease, including patients with heart block, cardiac arrhythmia and those who have experienced a recent myocardial infarction.
Section 2 of the corresponding PIL should always contain the following information for patients:
This medicine may be associated with thoughts of self-harm and suicidal behaviour in some people.
Tell someone you trust, who can help you in an emergency, that you are taking this medicine and ask that they read this leaflet
Talk to your trusted person, prescriber or go to a hospital straight away, if after starting this medicine, you have new or worse:
• Feelings of anxiety or irritability
• Feelings of restlessness and agitation
• Extreme increases in activity and difficulty sleeping
• Thoughts of acting on dangerous impulses to harm yourself
• Thoughts about suicide or dying
• Changes in behaviour or mood you, or someone you trust, notices and is worried about
In some people, thoughts of self-harm and suicidal behaviour may be increased when first starting antidepressants. Antidepressants take time to work; and sometimes side effects occur before you or others notice improvements in your mood.
Never stop taking an antidepressant suddenly without first talking to a healthcare professional. Stopping an antidepressant medicine suddenly can cause other symptoms related to withdrawal to occur.
Information from clinical trials has shown the highest risk of thoughts of self harm and suicidal behaviour, is in adults aged less than 25 years who were treated with an antidepressant but the risk applies to people of all ages treated with these medicines.
Call NHS 111 who can offer you support, until you can be with someone who can help you in person.
In addition to the above text for section 2 of the PIL a headline should be at the top of the PIL in a box to contain the following information
| Warning – Thoughts of self- harm and suicidal behaviour – see section 2 |
Serotonin syndrome
Concomitant administration of Doxepin 50 mg Capsules and buprenorphine/ opioids may result in serotonin syndrome, a potentially life-threatening condition (see section 4.5).
If concomitant treatment of buprenorphine/ opioids is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Symptoms of serotonin syndrome may include mental-status changes, autonomic instability, neuromuscular abnormalities, and/or gastrointestinal symptoms.
If serotonin syndrome is suspected, a dose reduction or discontinuation of therapy should be considered depending on the severity of the symptoms.
Hepatic/renal impairment
Use with caution in patients with hepatic and/or renal impairment.
Patients with epilepsy
Use with caution in patients with a history of epilepsy.
Since suicide is an inherent risk in any depressed patient until significant improvement has occurred, patients should be closely supervised during early therapy.
Patients with benign prostatic hyperplasia may experience an increase in associated urinary retention (see 'Undesirable effects').